Artivion, Inc.

What Artivion, Inc. does

Artivion, Inc. (NYSE: AORT), headquartered in Kennesaw, Georgia and founded in 1984 as CryoLife, Inc., is a medical device company specializing in cardiac and vascular surgery products, with an explicit strategic focus on aortic disease. The company's portfolio spans heart valve solutions (On-X mechanical valves, Chord-X chordal replacement, CryoValve allografts), cardiac and vascular allografts (CryoPatch, CryoGraft, CryoArtery, CryoVein), aortic arch solutions (NEXUS, NEXUS TRE, NEXUS DUO, AMDS Hybrid Prosthesis, Neo EDE, E-vita Open Neo), thoracoabdominal and abdominal stent grafts (E-tegra, E-liac, E-nside TAAA, E-xtra Design, Artivex, Tuva BX), surgical sealants (BioGlue), and ancillary products (PhotoFix decellularized bovine pericardium, CarbonAid CO2 diffusers, guidewires, balloons). Proprietary technology platforms include SynerGraft detergent-free decellularization, PhotoFix dye-mediated photo-oxidation (aldehyde-free), and the Dock & Lock NEXUS branched endovascular architecture.

The company operates two reportable segments—Medical Devices and Preservation Services—and distributes products in more than 100 countries through a direct field-sales force targeting cardiac and vascular surgery departments, supplemented by select exclusive distribution agreements (e.g., CarbonAid with Cardia Innovation AB). Artivion reports four wholly-owned subsidiaries: JOTEC GmbH (Germany), On-X Life Technologies (Austin, TX), Ascyrus Medical GmbH (Frankfurt, Germany), and Endospan Ltd. (Herzliya, Israel), the last of which was acquired in May 2026 for $135 million upfront plus contingent consideration following FDA Premarket Approval of the NEXUS Aortic Arch System in April 2026. Customers are hospitals and surgical centers (acute care hospitals with cardiac surgery programs, specialized heart hospitals, and vascular surgery centers), with end-users being cardiothoracic and vascular surgeons performing open-heart surgery, aortic repair, and minimally invasive endovascular procedures. Pricing is not publicly disclosed and is typically negotiated through hospital procurement and GPO contracts. Full-year 2025 adjusted revenue was $443.6 million (up 13% on a constant currency basis), Q1 2026 revenue was $116.34 million (up 17.54% YoY), and FY2026 guidance is $480-496 million, with adjusted EBITDA of approximately $90 million (up 26% YoY) in FY2025.

Name

Artivion, Inc.

Legal name

Artivion, Inc.

Website

https://artivion.com

Company type

Public

Founded year

1984

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Artivion is a publicly traded medical device company (NYSE: AORT) that develops and markets cardiac and vascular surgery products—heart valves, cryopreserved allografts, aortic arch stent grafts, and surgical sealants—for hospitals and cardiac/vascular surgeons across 100+ countries, with an aortic-focused portfolio.

Ownership category

akta.pro rank

Product category

Cardiovascular Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Cardiac Surgery Devices (Cannulas, Clamps, Closure, Grafts) (HLAHAFAH)

akta.pro secondary industry

Surgical Stapling, Suturing & Hemostasis (Staplers, Clips, Sealants, Tourniquets) (HLAHADAL)

Keywords

• Cardiac surgery devices
• Vascular stent grafts
• Heart valve replacement
• Cryopreserved tissue allografts
• Surgical sealants adhesives

Headquarters

HQ city

Kennesaw

HQ country

United States

HQ region

North America

Offices7 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Medical Devices: Manufactures and distributes medical devices including stent grafts, heart valves, surgical sealants, and vascular grafts for cardiac and vascular surgery. Revenue generated through product sales to hospitals and surgical centers.
2. Preservation Services (Implantable Human Tissues): Processes and distributes cryopreserved human tissues including heart valves, saphenous veins, femoral veins, arteries, and pericardial patches for surgical procedures.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Artivion manufactures and distributes medical devices and implantable human tissues for cardiac and vascular surgery. Its portfolio includes mechanical heart valves (ON-X), aortic arch stent graft systems (NEXUS, AMDS), thoracoabdominal and abdominal stent grafts, surgical adhesives (BioGlue), and cryopreserved human tissue allografts (CryoValve, CryoPatch, CryoVein, CryoArtery). The company operates two reportable segments: Medical Devices and Preservation Services, selling primarily to hospitals and surgical centers in over 100 countries.

Product overview

Artivion, Inc. is a medical device company specializing in cardiac and vascular surgery products. The portfolio is organized into multiple interconnected product lines: Heart Valve Solutions (ON-X mechanical valves, Chord-X chordal replacement, CryoValve allografts), Allografts for Cardiac & Vascular reconstruction (CryoPatch patches, CryoGraft, CryoArtery, CryoVein for various surgical applications), Aortic Arch solutions (NEXUS platform including NEXUS, NEXUS TRE, NEXUS DUO; AMDS Hybrid Prosthesis, Neo EDE, E-vita Open Neo), Thoracic and Abdominal Stent Grafts (E-tegra, E-liac, E-nside TAAA, E-xtra Design, Artivex, Tuva BX), Surgical Sealants (BioGlue), and Ancillary Products (PhotoFix, CarbonAid, guidewires, balloons, vascular grafts). The company operates two reportable segments: Medical Devices and Preservation Services.

Differentiator

Problem solved

Functional benefit

Brands

• On-X: Heart valve products including mechanical heart valves for aortic and mitral valve replacement
• NEXUS
• AMDS
• BioGlue
• CryoValve
• CryoPatch
• CryoVein
• CryoArtery

Products and services

• NEXUS Aortic Arch Stent Graft System An endovascular branched stent graft system specifically designed for the aortic arch, featuring a bimodular architecture with an aortic arch component and ascending aorta component for endovascular repair of aortic arch disease.
• AMDS Hybrid Prosthesis The world's first aortic arch remodeling device specifically designed for treating acute DeBakey Type I aortic dissections with malperfusion, featuring a PTFE felt cuff and uncovered nitinol wire braided stent.
• ON-X Aortic Heart Valve Mechanical aortic heart valve with recent 24% growth driven by new clinical data supporting mechanical valve use for patients under 65.
• ON-X Mitral Heart Valve Mechanical mitral valve replacement device for patients requiring mitral valve surgery.
• CryoValve SG Pulmonary Human Heart Valve The first and only decellularized human heart valve to receive 510(k) clearance from FDA, featuring SynerGraft technology for superior freedom from reintervention.
• CryoValve Aortic Allograft Cryopreserved aortic allograft ideal for endocarditis patients, demonstrating 85.2% freedom from recurrent endocarditis at 20 years.
• CryoPatch SG Pulmonary Patch SynerGraft decellularized pulmonary patch for congenital cardiac reconstruction, reducing panel reactive antibodies.
• CryoPatch Autologous Pericardium Cryopreserved autologous pericardium for pediatric cardiac surgery reconstruction, with low immunogenicity and minimal calcification tendency.
• CryoGraft Descending Thoracic Aorta Cryopreserved descending thoracic aorta allograft for cardiovascular reconstruction with natural suturability and compliance.
• CryoArtery Aortoiliac Artery Cryopreserved aortoiliac artery for infected field replacement, demonstrating 96% freedom from reinfection and 97% patency at 5 years.
• CryoArtery Femoral Artery Cryopreserved femoral artery for below-knee revascularization with 100% freedom from infection at 3 years.
• CryoVein Saphenous Vein Cryopreserved saphenous vein for peripheral bypass below the knee, demonstrating 87% 1-year primary patency and high limb salvage rates.
• CryoVein Femoral Vein Cryopreserved femoral vein for infected AV access graft replacement, with 72% 2-year cumulative patency.
• CryoVein PC Pediatric Conduit Cryopreserved pediatric conduit demonstrating improved pulmonary artery growth compared to PTFE grafts.
• NEXUS TRE Aortic Arch Stent Graft System A custom-made aortic arch stent graft engineered for total endovascular aortic arch repair with 100% percutaneous treatment capability, featuring integrated branch design and Dock & Lock technology.
• NEXUS DUO Aortic Arch Stent Graft System A custom-made device building on NEXUS technology with double branch configuration designed to mitigate stroke risk in aortic arch repair procedures.
• Neo EDE Hybrid Arch Device A custom-made hybrid arch device that simplifies complex frozen elephant trunk procedures, manufactured by JOTEC GmbH with 22 working day production time.
• E-vita Open Neo Hybrid Stent Graft System A next-generation hybrid graft system for aortic arch and descending thoracic aorta repair using the Frozen Elephant Trunk technique, with three stent graft configurations.
• E-tegra Stent Graft System Abdominal aortic stent graft with W-shaped proximal stent design and 360-degree asymmetrical spring design for flexibility.
• E-liac Stent Graft System Iliac branch device for aorto-iliac and isolated iliac aneurysms with high patency rates and low reintervention rates.
• E-nside TAAA Multibranch Stent Graft System First pre-cannulated, inner branch-based off-the-shelf solution for thoracoabdominal aneurysms.
• Artivion Tuva BX Peripheral Stent ePTFE covered peripheral stent with high flexibility and open cell design for treating tortuous arteries.
• BIOGLUE Surgical Adhesive The only surgical sealant approved to seal, adhere and reinforce tissue, with over 500 published clinical papers supporting its use.
• PhotoFix Decellularized Bovine Pericardium Photo-oxidized decellularized bovine pericardium using dye-mediated photo-oxidation that eliminates aldehyde chemistry, ready to use without rinsing or rehydrating.
• Chord-X Mitral Chordal Replacement Products Mitral chordal replacement products designed to standardize, simplify and save time during mitral valve repair procedures, available in pre-measured loops and adjustable suture systems.
• ON-X Ascending Aortic Prosthesis Ascending aortic prosthesis for cardiac surgery.

Quantifiable outcome

• 94% patient survival from lesion-related death at 1 year using NEXUS Aortic Arch System (NEXUS TRIOMPHE IDE trial)
• +5 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

One partnership is on record.

• Endospan Ltd.coreStrategic or Co-development Partner · 18 May 2026Endospan was Artivion's long-standing partner for endovascular repair of aortic arch disease and developer of the NEXUS Aortic Arch System. Artivion exercised its option to acquire Endospan following FDA PMA approval of NEXUS in April 2026, completing the acquisition on May 18, 2026 for $135 million upfront plus contingent consideration based on commercial performance.

Scale indicators14 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Medtronic: Medtronic is a diversified medtech incumbent with substantial cardiac surgery, vascular, and aortic franchises (including Valiant Navion thoracic stent graft and Endurant AAA). Overlaps with Artivion across stent grafts and heart valves but as part of a much broader portfolio.
• Abbott Vascular: Abbott's structural heart and vascular businesses (Amplatzer, Portico, MitraClip) compete across several of Artivion's cardiac surgery and peripheral vascular segments. A large diversified incumbent rather than a focused aortic specialist.

Direct peers

• Terumo Aortic: Terumo Aortic (formerly Vascutek) manufactures the Relay thoracic stent graft and Anaconda AAA device, and is one of the closest direct competitors in the aortic stent graft space alongside Gore and Cook.
• Edwards Lifesciences: Edwards Lifesciences is a global leader in heart valves (including transcatheter aortic valve replacement) and critical care monitoring. Directly comparable to Artivion in the structural heart / surgical valve space, and a competitor for aortic and cardiac surgery procedure volume.
• W. L. Gore & Associates: Gore is the incumbent in endovascular stent grafts (GORE EXCLUDER AAA, GORE TAG thoracic) and a key competitor for Artivion's E-tegra, E-nside TAAA, and NEXUS platforms. Comparable in vascular graft materials science and aortic intervention.
• LivaNova: LivaNova produces heart valves (Perceval, Memo 3D), cardiopulmonary products, and advanced circulatory support. Comparable to Artivion's ON-X mechanical heart valve franchise and broader cardiac surgery portfolio.
• Cook Medical: Cook Medical is a privately held medical device manufacturer with strong aortic intervention and stent graft offerings (Zenith platform). Directly competes with Artivion in the thoracoabdominal and abdominal aortic stent graft segments.

Emerging players

• InspireMD: InspireMD focuses on carotid and vascular stent systems (CGuard). Smaller and earlier-stage than Artivion, with overlapping interest in endovascular stent delivery and embolic protection, but focused on carotid rather than aortic disease.
• Penumbra: Penumbra is a vascular thrombectomy and embolization specialist. Partial overlap with Artivion's peripheral vascular (CryoVein, Tuva BX) and aortic segments, with a more procedure-focused, endovascular toolkit.

Others

• AtriCure: AtriCure specializes in cardiac surgery ablation and left atrial appendage management. Adjacent to Artivion in cardiac surgery but with limited direct product overlap; thematically comparable as a cardiac surgery-focused medtech.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/ArtivionInc
• LinkedInlinkedin.com/company/artivion-emea

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Artivion, Inc.